

Area Drugs and Therapeutics Committee Meeting Minutes


Wednesday 21st May 2025 10-12.30pm

Microsoft Teams Meeting

| | | |
|-----------|--|--|
| | Present | |
| | Graeme Bryson (Interim Chair) Rachael Kelly Craig Thurtell Craig Kinstree (on behalf of Sharon Murray) David Semple Kirsty Macfarlane Kelly Baillie Lorna Templeton-item 8g Liz McIntyre-item 8a | Victoria Gemmell (Prof Sec) Stephanie Dundas Chris Miller Tyra Smyth Carol Stewart Penny Brankin Eimear Gordon (on behalf of Gail Richardson) |
| 1. | Apologies | |
| | Sharon Murray, Colin Angus, Gail Richardson, Alistair Brown | |
| 2. | Declaration of Interest | |
| | nil | |
| 3. | Ratification of minutes of March meeting | |
| | <p>March Minutes-Attendance of Craig Thurtell to be added. These were agreed as a true reflection of the meeting and can be published.</p> <p>ADTC Meeting on 23rd April 2025 was cancelled. Some documents were circulated for virtual review and approval. The following documents were approved;</p> <ul style="list-style-type: none"> • Thrombolysis and Thrombectomy Pathway (V 1.7) • SACT Policy <p>SMC Advice and NCMAG Advice was also circulated for noting by the committee and will move through the usual processes.</p> | |
| 4. | Matters arising not covered elsewhere on the agenda | |
| a) | Vabysmo – Update awaited | |
| b) | Hyperacute Stroke – Alteplase Guidance for Patients Requiring Thrombolysis – Alternative to Tenecteplase – Mark Barber / Gary Lynas– Update awaited | |
| c) | Administration of S/C Intermittent Medication in Adult Palliative Care Policy - Linda Johnstone Approved with no further changes | |
| d) | Ryeqo Clinical Protocol – Mihai Gherghe This was deferred after further communication from the submitting team. | |
| e) | NHSL Asthma Treatment Guide – Andrew Smith This was approved with no further changes. | |
| 5. | ADTC Committee Business | |
| | Recruitment for new ADTC Chair is underway, with plans for a new Chair to be in place for the June meeting. Chris Miller has been nominated and accepted as Vice Chair for ADTC from May 2025. The Pharmacy ADTC support team met to take forward plans for a revised structure with new Terms of Reference to be presented for approval at the June meeting. | |

| | | | | |
|--------------|---|-------------------------------|--|----------------------|
| 6. | SMC Advice - CONFIDENTIAL | | | |
| 6.1a | FULL SUBMISSIONS | | | |
| | Medicine | Manufacturer | Indication in brief | SMC reference |
| | durvalumab concentrate for solution for infusion (Imfinzi) | AstraZeneca | In combination with tremelimumab for the first-line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC). | SMC2735 |
| | ruxolitinib tablets (Jakavi) | Novartis | for the treatment of patients aged 12 years and older with acute graft versus host disease who have inadequate response to corticosteroids. | SMC2750 |
| | cladribine 10mg tablet (Mavenclad) | Merck | for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease as defined by clinical or imaging features. | SMC2751 |
| | selpercatinib hard capsules (Retsevmo) (MTC) | Eli Lilly and Company Limited | as monotherapy for the treatment of adults and adolescents 12 years and older with advanced rearranged during transfection (RET)-mutant medullary thyroid cancer (MTC). | SMC2732 |
| 6.1.b | ABBREVIATED SUBMISSIONS | | | |
| | Medicine | Manufacturer | Indication in brief | |
| | sumatriptan 85mg / naproxen 457mg (Suvexx) | Orion Pharma UK Ltd | the acute treatment of the headache phase of migraine attacks with or without aura in adults where treatment with a mono-entity product has been insufficient. | |
| 6.1.c | NON SUBMISSIONS | | | |
| | Medicine | Manufacturer | Indication in brief | |
| | bempedoic acid film-coated tablets (Nilemdo) | Daiichi Sankyo UK Limited | in adults with established or at high risk for atherosclerotic cardiovascular disease to reduce cardiovascular risk by lowering LDL-C levels, as an adjunct to correction of other risk factors: in patients on a maximum tolerated dose of a statin with or without ezetimibe or, alone or in combination with ezetimibe in | |

| | | | patients who are statin-intolerant, or for whom a statin is contraindicated | | | | | | | | | | | | | | | | | | | | | |
|-----------------------|--|---------------------------|--|------------------------------------|------------------------------|---|---------|-----------------------|------------------------------------|---------------------------------|---------------------------------|-------------------------|---------------------|---------------------|------------------|-----------------------|--|------------|--|-----------------------------|------------------------------|---|----|--------|
| | bempedoic acid / ezetimibe film-coated tablets (Nustendi) | Daiichi Sankyo UK Limited | in adults with established or at high risk for atherosclerotic cardiovascular disease to reduce cardiovascular risk by lowering LDL-C levels, as an adjunct to correction of other risk factors: in patients on a maximum tolerated dose of a statin and not adequately controlled with additional ezetimibe treatment or, in patients who are either statin-intolerant, or for whom a statin is contraindicated, and not adequately controlled with ezetimibe treatment or, in patients already being treated with the combination of bempedoic acid and ezetimibe as separate tablets. | | | | | | | | | | | | | | | | | | | | | |
| | pegylated liposomal irinotecan (Onivyde) | Servier Laboratories Ltd | in combination with oxaliplatin, 5-fluorouracil (5-FU) and leucovorin (LV) for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas. | | | | | | | | | | | | | | | | | | | | | |
| | pegzilarginase solution for injection/infusion (Loargys) | Immedica AB | treatment of arginase 1 deficiency (ARG1-D), also known as hyperargininemia, in adults, adolescents and children aged 2 years and older. | | | | | | | | | | | | | | | | | | | | | |
| 6.1.d | <p>WITHHELD</p> <p>bevacizumab gamma (Lytenava) Outlook Therapeutics Limited SMC2744 ABBREVIATED</p> <p>The submitting company has advised SMC that product availability has been delayed therefore publication of the Advice Document, previously scheduled for 12 May, 2025 will be delayed. Please continue to keep this advice confidential and an updated version will be circulated when the medicine is available for use.</p> | | | | | | | | | | | | | | | | | | | | | | | |
| 6.1.e | <p><u>Paediatric License Extensions</u></p> <p>This was noted and will be communicated to paediatric colleagues.</p> <table><tr><th rowspan="2">Product</th><th rowspan="2">Formulation</th><th rowspan="2">Company</th><th rowspan="2">Paediatric indication</th><th rowspan="2">CHMP positive opinion¹</th><th rowspan="2">Availability in UK²</th><th colspan="2">Adults/older age groups</th><th rowspan="2">NHS Boards Informed</th></tr><tr><th>SMC advice</th><th>PAS³</th></tr><tr><td>dalbavancin (Xydalba)</td><td>500mg powder for concentrate for solution for infusion</td><td>AbbVie Ltd</td><td>Treatment of acute bacterial skin and skin structure infections (ABSSSI) in paediatric patients from birth to 3 months</td><td>(27 Mar-25)</td><td>Awaiting update from company</td><td>Accepted Restricted 1105/15</td><td>No</td><td>May-25</td></tr></table> | | | | Product | Formulation | Company | Paediatric indication | CHMP positive opinion ¹ | Availability in UK ² | Adults/older age groups | | NHS Boards Informed | SMC advice | PAS ³ | dalbavancin (Xydalba) | 500mg powder for concentrate for solution for infusion | AbbVie Ltd | Treatment of acute bacterial skin and skin structure infections (ABSSSI) in paediatric patients from birth to 3 months | (27 Mar-25) | Awaiting update from company | Accepted Restricted 1105/15 | No | May-25 |
| Product | Formulation | Company | Paediatric indication | CHMP positive opinion ¹ | | | | | | | Availability in UK ² | Adults/older age groups | | NHS Boards Informed | | | | | | | | | | |
| | | | | | SMC advice | PAS ³ | | | | | | | | | | | | | | | | | | |
| dalbavancin (Xydalba) | 500mg powder for concentrate for solution for infusion | AbbVie Ltd | Treatment of acute bacterial skin and skin structure infections (ABSSSI) in paediatric patients from birth to 3 months | (27 Mar-25) | Awaiting update from company | Accepted Restricted 1105/15 | No | May-25 | | | | | | | | | | | | | | | | |

| | | |
|---|---|--|
| 6.1.f | <p>Collaborative Advice</p> <p>SMC has issued an updated Collaborative Advice Document for nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19.</p> <p>This was noted.</p> <p>These updated recommendations supersede the advice provided to boards regarding the funding variation by Scottish Government on 14th March 2024.</p> <p>New SMC Decisions were discussed and RK will proceed with post-ADTC discussions with the relevant specialists to discuss the use of approved medicines within the board.</p> <p>There was specific discussion around SMC2750 ruxolitinib tablets, wherein the potential routes to this medicine in NHS Lan were covered. It was noted that this SMC advice would not go through PASG, and that initiation of this medicine would not be expected in NHS Lan, and that clinicians would look to other specialists regarding recommendations for its use for Lanarkshire patients. It was agreed that RK will contact local specialists to confirm this to confirm appropriate Lanarkshire designation.</p> <p>The not recommended advice for SMC2740 bempedoic acid and SMC2741 bempedoic acid/ezetimibe were noted specifically given that reference is made to bempedoic acid in the 'NHSL Guideline for the Management of Cholesterol in adults'. RK will explore the implications for this and report back to the committee with any actions required.</p> | |
| 6.2 | <p>Updates to NHSL status on SMC advice AND ADTC NEW MEDICINES DECISIONS</p> <p>RK outlined proposed Lanarkshire designation updates. This was accepted.</p> | |
| 7. | <p>Lanarkshire Formulary / West of Scotland Formulary</p> | |
| <p>7.1.a</p> <p>7.1.b</p> <p>7.1.c</p> <p>7.1.d</p> <p>7.1.e</p> <p>7.1.f</p> | <p>NHSLK formulary changes proposals</p> <p>Benzo + Z drug Quality Prescribing Links to guide</p> <p>CGM Criteria T2DM</p> <p>Formulary Amendment Form Anthelios April 2025</p> <p>Formulary Amendment Form Flexitol April 2025</p> <p>IM Thiamine (Pabrinex IM Discontinuation)</p> <p>RK presented the formulary proposed updates. These papers were accepted.</p> <p>The committee discussed the proposed addition of Thiamine solution for IM injection, in response to the discontinuation of IM Pabrinex, in particular the request to update the formulary category for this replacement drug. The committee agreed that it would be appropriate to maintain the formulary category for this as an S2 category medicine. It was agreed that this formulary category accurately reflected the place of this medicine within the service, and provision via PGDs was noted. It was agreed that the clinicians would be notified to appeal to the committee if required. The decision to accept this formulary amendment without updating the formulary category was viewed as appropriate as to not delay necessary formulary updates in light of the discontinuation of the drug.</p> | |
| 7.2 | <p><u>West of Scotland Formulary Updates</u></p> <p>7.2.1 Terms of Reference Final</p> <p>These were noted.</p> <p>7.2.2 Nomination for Chapter Expert Working Groups</p> <p> Nominations for Chapter Expert Working Groups</p> | |

| | | |
|-------|---|--|
| 7.2.3 | <p>Details of this has been shared widely across the Board, requesting nominations from NHSL clinicians.</p> <p>Board Minutes – April 2025 These were noted.</p> | |
| 8. | Clinical Protocols & Guidelines | |
| | <p><u>Carried over from April Meeting</u></p> <p>a) Use of Insulin Pump Systems in Acute Hospitals – Elizabeth McIntyre</p> <ol style="list-style-type: none"> 1. IP Pump Guideline Summary 2. ADTC form Guidelines Submission 3. Appendix 1 – Assessment of Type 1 Diabetes Patient with Insulin Pump Therapy 4. Appendix 2 – Insulin Pump Daily Review Checklist 5. Appendix 3 – Pump management for elective procedures under sedation or general anaesthesia 6. Appendix 4 – Unexplained Hyperglycaemia and Sick day rules (Hybrid Closed Loop 7. Appendix 5 – Unexplained Hyperglycaemia and Sick Day rules Standalone Insulin Pump 8. JBDS guidelines, copyright statement (for info) <p>Some small formatting points were raised. The documents are all approved pending these changes. Final docs to be returned for filing and noting under matters arising.</p> <p>b) Diabetes Pre op guideline – Clare Carson / Babu Mukhopadhyay There was a request to add tirzepatide to the list of GLP-1 medicines. Approved pending this change.</p> <p>c) Prophylaxis of Acid Aspiration for Maternity Patients – Hannah Fulton Approved subject to updating governance info on footer and rear of document.</p> <p>d) Maternal Sepsis and Pyrexia Management – Hannah Fulton Some small spelling and grammatical errors. Governance info and change record to be completed. Approved pending these changes.</p> <p>e) Lebrikizumab – Carol Martin The use of this was approved; however, the committee issued a formal recommendation that a comprehensive treatment pathway must be developed and presented at the next ADTC meeting.</p> <p>f) Prescribing of Valproate in Patients of Childbearing Age – Adam Daly This was approved with no changes.</p> <p>g) SBAR Developing ‘Once for Scotland’ Mental Health Medication Guidance – Lorna Templeton LT gave an overview of plans to develop national mental health medication guidance for use across Boards. Most Boards have similar guidance so this work would streamline and unify these documents. It was agreed the committee support the principle of taking this work forward.</p> | |

| | | |
|-----|---|-----------------|
| | <p><u>New for May</u></p> <p>h) Treatment Pathway for Axial Spondyloarthritis (Ankylosing Spondylitis) Non Radiographic Axial Spondyloarthritis – Sanjiv Nandwani This was approved with no changes.</p> <p>i) IBD Vaccination Guideline – Lauren Fortune This was not approved. The committee were not clear on the purpose of the guideline, and recommend engagement with the vaccination services.</p> <p>j) Paediatric Acute Pain PCA analgesia and antiemetic guideline – Colum Slorach This was approved with no further changes.</p> | |
| 9. | <u>New Medicine Safety Notifications & Alerts</u> | GR B |
| 9.a | <p>CAS - Home</p> <p>MHRA Updates</p> <p>b. https://www.gov.uk/drug-safety-update</p> <p>c. NPSA Alert– Discontinuation of Promixin VG to find out more information and feedback.</p> <p>d. Medicines Related Communications to Health Boards-standing item It was discussed that the Central Pharmacy team, the DOP corporate team and business support will be working with the Executive Medical director to review the cascading of emails relating to safety alerts etc.</p> | |
| 10. | Prescribing Management Board Update | |
| a. | nil | |
| 11. | Medicines for the Treatment of Cancer | |
| a. | <p>NCMAG122 An error in the original trial data was identified in the published advice. The guidance document was updated to reflect this This was noted.</p> <p>b. RCAG NIL</p> <p>c. Cancer Related Guidelines</p> <p>1. Mucositis Guideline – Kelly Ballie This is an update to a previous version. It was approved with no changes. A comment was raised regarding medicines included on the Medicines of Low Clinical Value guidance and if that would affect prescribing of any items. CM will take this forward and feedback.</p> <p>2. Adult systemic anti-cancer (SACT) induced anaphylaxis guideline – Kelly Ballie These are updates to a previous version. A comment was raised regarding fluid availability in the ward area. This will be reviewed. There was also a discussion on the wording around supervision of the patient.</p> | |

| | | |
|-------------|--|--|
| | The document was approved subject to points of clarification. | |
| 12. | Non-Medical Prescribing | |
| | nil | |
| 13. | PGD Activity Report | |
| a. | Community Pharmacy Process – Ellen Jo Fowler KM gave an update on the statement. A point was raised regarding the requirement of confirmation that a CP has signed up to use a PGD. Community Pharmacies are independent contractors and so may be better placed to manage their own obligations to operate legally. | |
| b. | KM gave an update regarding the changes to PGD process. The team have extensively communicated the need for teams to notify the Meds Guidance team about all and any PGD's in use by clinical areas. There was a request to feedback if there were any other mechanism of communication that would be helpful. Going forward, a monthly briefing paper will be presented b team. | |
| 14. | Antimicrobial Management Team Update | |
| a. | Rezafungin – Stephanie Dundas The document was approved. | |
| 15. | Lay member related items | |
| | Nil | |
| 16. | AOCB | |
| 16a. | ULM –Acetylcholine for Ophthalmology- Ruth Waters Approved for use for six months. Further use will require a further application. | |
| 16b. | ULM – Nystatin pessaries for Vaginal Candidiasis Michael Hillhouse This was approved. | |
| 16c. | NHSL patient leaflet – Kirsty MacFarlane This was refresh of a previous version. This was noted. | |
| 17. | Date of next meeting | |
| | Wednesday 18 th June 2025 10-12.30pm MS TEAMS | |